(MDGL) Madrigal Pharmaceuticals - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US5588681057

Stock: Rezdiffra, MASH, Thyroid, Receptor, Agonist

Total Rating 41
Risk 30
Buy Signal -0.48
Biotechnology » Biotechnology
Age: 19y
Market Cap: 11,113m
Avg Trading Vol: 154M USD
ATR: 4.41%
Peers RS (IBD): 42.00

EPS (Earnings per Share)

EPS (Earnings per Share) of MDGL over the last years for every Quarter: "2020-12": -3.82, "2021-03": -3.32, "2021-06": -3.72, "2021-09": -3.79, "2021-12": -3.78, "2022-03": -3.36, "2022-06": -4.14, "2022-09": -4.75, "2022-12": -4.98, "2023-03": -4.23, "2023-06": -4.69, "2023-09": -5.34, "2023-12": -5.68, "2024-03": -7.38, "2024-06": -7.1, "2024-09": -4.92, "2024-12": -2.71, "2025-03": -3.32, "2025-06": -1.9, "2025-09": -4.9555, "2025-12": 0,
EPS CAGR: 16.06%
EPS Trend: 45.3%
Last SUE: 0.38
Qual. Beats: 0

Revenue

Revenue of MDGL over the last years for every Quarter: 2020-12: 0, 2021-03: 0.273, 2021-06: 0.01011, 2021-09: 0.008287, 2021-12: 3.732E-5, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.77, 2024-03: 0, 2024-06: 14.638, 2024-09: 62.175, 2024-12: 103.32, 2025-03: 137.25, 2025-06: 212.802, 2025-09: 287.268, 2025-12: null,
Rev. CAGR: 6760.55%
Rev. Trend: 87.8%
Last SUE: 2.18
Qual. Beats: 3
Risk 5d forecast
Volatility 54.8%
Relative Tail Risk -8.88%
Reward TTM
Sharpe Ratio 0.92
Alpha 27.41
Character TTM
Beta 0.778
Beta Downside 0.677
Drawdowns 3y
Max DD 61.41%
CAGR/Max DD 0.38

Description: MDGL Madrigal Pharmaceuticals January 09, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) is a U.S.-based biopharma focused on metabolic-dysfunction-associated steatohepatitis (MASH). Its lead asset, Rezdiffra, is a liver-directed thyroid hormone receptor-beta agonist designed to treat MASH, and the company is headquartered in West Conshohocken, Pennsylvania.

Key metrics: as of the latest filing, MDGL has a market capitalization of roughly $1.2 billion and a cash runway extending into 2025, supporting ongoing Phase III trials. The MASH market is projected to exceed $10 billion globally by 2030, driven by rising obesity and diabetes prevalence-macro trends that underpin demand for novel liver-targeted therapies. The broader biotechnology sector is benefitting from heightened investor appetite for specialty drugs with differentiated mechanisms of action, which could amplify Madrigal’s valuation upside if trial endpoints are met.

For a deeper dive into Madrigal’s valuation dynamics and comparable peer analysis, you may find ValueRay’s research platform a useful next step.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income: -289.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.12 > 0.02 and ΔFCF/TA 28.98 > 1.0
NWC/Revenue: 129.0% < 20% (prev 1142 %; Δ -1013 % < -1%)
CFO/TA -0.12 > 3% & CFO -160.6m > Net Income -289.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 3.44 > 1.5 & < 3
Outstanding Shares: last quarter (22.5m) vs 12m ago 3.39% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 60.81% > 50% (prev 7.23%; Δ 53.59% > 0%)
Interest Coverage Ratio: -15.51 > 6 (EBITDA TTM -270.1m / Interest Expense TTM 17.5m)

Altman Z'' -4.66

A: 0.70 (Total Current Assets 1.35b - Total Current Liabilities 391.4m) / Total Assets 1.36b
B: -1.49 (Retained Earnings -2.03b / Total Assets 1.36b)
C: -0.22 (EBIT TTM -271.6m / Avg Total Assets 1.22b)
D: -2.76 (Book Value of Equity -2.03b / Total Liabilities 736.7m)
Altman-Z'' Score: -4.66 = D

Beneish M 1.00

DSRI: 0.39 (Receivables 113.3m/30.5m, Revenue 740.6m/77.6m)
GMI: 1.01 (GM 95.25% / 96.01%)
AQI: 1.22 (AQ_t 0.01 / AQ_t-1 0.00)
SGI: 9.55 (Revenue 740.6m / 77.6m)
TATA: -0.09 (NI -289.1m - CFO -160.6m) / TA 1.36b)
Beneish M-Score: 2.64 (Cap -4..+1) = D

What is the price of MDGL shares?

As of February 08, 2026, the stock is trading at USD 477.60 with a total of 338,615 shares traded.
Over the past week, the price has changed by -2.39%, over one month by -14.41%, over three months by -2.25% and over the past year by +44.61%.

Is MDGL a buy, sell or hold?

Madrigal Pharmaceuticals has received a consensus analysts rating of 4.47. Therefore, it is recommended to buy MDGL.
  • StrongBuy: 10
  • Buy: 3
  • Hold: 1
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the MDGL price?

Issuer Target Up/Down from current
Wallstreet Target Price 657.1 37.6%
Analysts Target Price 657.1 37.6%
ValueRay Target Price 572.2 19.8%

MDGL Fundamental Data Overview February 03, 2026

P/E Forward = 666.6667
P/S = 15.0045
P/B = 17.9552
Revenue TTM = 740.6m USD
EBIT TTM = -271.6m USD
EBITDA TTM = -270.1m USD
Long Term Debt = 339.8m USD (from longTermDebt, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 346.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 50.7m USD (from netDebt column, last quarter)
Enterprise Value = 10.35b USD (11.11b + Debt 346.4m - CCE 1.11b)
Interest Coverage Ratio = -15.51 (Ebit TTM -271.6m / Interest Expense TTM 17.5m)
EV/FCF = -64.03x (Enterprise Value 10.35b / FCF TTM -161.6m)
FCF Yield = -1.56% (FCF TTM -161.6m / Enterprise Value 10.35b)
FCF Margin = -21.82% (FCF TTM -161.6m / Revenue TTM 740.6m)
Net Margin = -39.04% (Net Income TTM -289.1m / Revenue TTM 740.6m)
Gross Margin = unknown ((Revenue TTM 740.6m - Cost of Revenue TTM 35.1m) / Revenue TTM)
Tobins Q-Ratio = 7.60 (Enterprise Value 10.35b / Total Assets 1.36b)
Interest Expense / Debt = 2.15% (Interest Expense 7.45m / Debt 346.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -214.6m (EBIT -271.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.44 (Total Current Assets 1.35b / Total Current Liabilities 391.4m)
Debt / Equity = 0.55 (Debt 346.4m / totalStockholderEquity, last quarter 625.7m)
Debt / EBITDA = -0.19 (negative EBITDA) (Net Debt 50.7m / EBITDA -270.1m)
Debt / FCF = -0.31 (negative FCF - burning cash) (Net Debt 50.7m / FCF TTM -161.6m)
Total Stockholder Equity = 696.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -23.74% (Net Income -289.1m / Total Assets 1.36b)
RoE = -41.50% (Net Income TTM -289.1m / Total Stockholder Equity 696.7m)
RoCE = -26.21% (EBIT -271.6m / Capital Employed (Equity 696.7m + L.T.Debt 339.8m))
RoIC = -24.66% (negative operating profit) (NOPAT -214.6m / Invested Capital 870.1m)
WACC = 8.57% (E(11.11b)/V(11.46b) * Re(8.78%) + D(346.4m)/V(11.46b) * Rd(2.15%) * (1-Tc(0.21)))
Discount Rate = 8.78% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.66%
Fair Price DCF = unknown (Cash Flow -161.6m)
EPS Correlation: 45.33 | EPS CAGR: 16.06% | SUE: 0.38 | # QB: 0
Revenue Correlation: 87.81 | Revenue CAGR: 6761 % | SUE: 2.18 | # QB: 3
EPS next Quarter (2026-03-31): EPS=-0.43 | Chg30d=+0.290 | Revisions Net=-3 | Analysts=5
EPS next Year (2026-12-31): EPS=2.69 | Chg30d=+0.253 | Revisions Net=+1 | Growth EPS=+124.9% | Growth Revenue=+54.4%

Additional Sources for MDGL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle